Skip to main content
    M

    MBX Biosciences, Inc. Common Stock (MBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $53.12
    -2.82 (-5.04%)

    Market Cap: $2.78B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MBX Biosciences, Inc. Common Stock (MBX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    MBX Biosciences, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$86.97M, operating cash flow was -$79.95M and free cash flow was -$81.88M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$62.42M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $98.06M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2022 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Cost of revenue$0$0$0$56.00K
    Gross profit$0$0$0-$56.00K
    Research and development$79.16M$57.41M$28.53M$21.40M
    Operating income-$98.06M-$68.19M-$35.31M-$25.16M
    Net income-$86.97M-$61.92M-$32.56M-$26.14M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$222.00K$0$0$0$0
    Gross profit$0$0$0-$60.00K$0$0$0$111.00K$0$0$0N/A
    Operating income-$66.34M-$40.93M-$27.27M-$25.80M-$23.93M-$21.80M-$26.53M-$18.61M-$19.61M-$16.66M-$13.31M-$9.99M
    Net income-$62.42M-$37.09M-$23.52M-$22.06M-$21.62M-$19.41M-$23.88M-$15.59M-$18.14M-$15.86M-$12.34M-$8.84M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $172.00K by $75.12M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Total assets$385.14M$268.54M$84.18M$45.09M
    Current assets$381.54M$267.29M$83.47M$44.21M
    Cash and equivalents$75.29M$49.35M$30.52M$24.21M
    Total liabilities$15.92M$11.09M$4.29M$87.70M
    Short-term debt$172.00K$171.00K$153.00K$137.00K
    Shareholder equity$369.22M$257.44M-$72.47M-$42.60M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$500.62M$435.91M$452.70M$385.14M$400.08M$231.52M$245.93M$268.54M$282.40M$62.88M$75.32M$84.18M
    Total liabilities$27.67M$26.37M$14.95M$15.92M$12.54M$12.28M$10.50M$11.09M$11.03M$160.77M$6.01M$156.65M
    Cash and equivalents$161.69M$54.12M$45.21M$75.29M$223.13M$39.78M$29.90M$49.35M$132.87M$12.50M$35.42M$30.52M
    Shareholder equity$472.95M$409.54M$437.76M$369.22M$387.54M$219.24M$235.42M$257.44M$271.37M-$97.89M$69.31M-$72.47M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Operating cash flow-$79.95M-$54.68M-$31.98M-$23.12M
    Capital expenditures$1.93M$874.00K$129.00K$441.00K
    Free cash flow-$81.88M-$55.55M-$32.11M-$23.56M
    Share repurchases$771.00K$4.06M$0N/A
    Investing cash flow-$83.70M-$160.59M-$30.93M-$11.41M
    Financing cash flow$189.59M$234.10M$69.22M$46.06M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$34.88M-$22.62M-$20.21M-$18.30M-$21.54M-$17.43M-$22.68M-$16.04M-$14.66M-$13.27M-$10.71M-$11.15M
    Capital expenditures$1.19M$901.00K$437.00K$793.00K$399.00K$707.00K$30.00K$92.00K$57.00K$452.00K$273.00K$55.00K
    Free cash flow-$36.07M-$23.52M-$20.64M-$19.09M-$21.93M-$18.14M-$22.71M-$16.13M-$14.72M-$13.72M-$10.98M-$11.20M
    Last 12 quarters

    Frequently Asked Questions About MBX

    What is MBX Biosciences, Inc. Common Stock's annual revenue?

    MBX Biosciences, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is MBX Biosciences, Inc. Common Stock profitable?

    No. MBX Biosciences, Inc. Common Stock reported net income of -$86.97M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does MBX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$79.95M minus capital expenditures of $1.93M produced free cash flow of -$81.88M.

    How much debt does MBX Biosciences, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $172.00K and cash and equivalents of $75.29M.